Does Rallies show Form 4 insider transactions for DNTH?

Yes. Rallies tracks DNTH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is DNTH research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DNTH. It does not provide personalized investment advice.

DNTH (Dianthus Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Dianthus Therapeutics, Inc. Common Stock (DNTH) is a publicly traded Healthcare sector company. As of May 21, 2026, DNTH trades at $88.72 with a market cap of $4.57B and a P/E ratio of -20.90. DNTH moved +3.53% today. Year to date, DNTH is +140.50%; over the trailing twelve months it is +364.26%. Its 52-week range spans $13.37 to $96.50. Analyst consensus is strong buy with an average price target of $122.57. Rallies surfaces DNTH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading DNTH stock inside the company?

Recent DNTH insider activity includes Soteropoulos Paula sold 599, Savitz Ryan sold 8.22K, Savitz Ryan sold 1.39K, Savitz Ryan sold 21.82K, and Savitz Ryan sold 1.49K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

DNTH Key Metrics

Key financial metrics for DNTH
Metric	Value
Price	$88.72
Market Cap	$4.57B
P/E Ratio	-20.90
EPS	$-4.22
Dividend Yield	0.00%
52-Week High	$96.50
52-Week Low	$13.37
Volume	0
Avg Volume	0
Revenue (TTM)	$1.34M
Net Income	$-173.66M
Gross Margin	0.00%

Recent DNTH Insider Trades

Soteropoulos Paula sold 599 (~$51.20K) on May 8, 2026.
Savitz Ryan sold 8.22K (~$738.84K) on Apr 9, 2026.
Savitz Ryan sold 1.39K (~$108.88K) on Mar 31, 2026.
Savitz Ryan sold 21.82K (~$1.72M) on Mar 31, 2026.
Savitz Ryan sold 1.49K (~$119.17K) on Mar 31, 2026.

Latest DNTH News

Dianthus Secures Orphan Status, Hits Early CIDP Go and Raises $719M — May 5, 2026
Dianthus Therapeutics slips as dilution overhang returns after March upsized offering and insider filings — Apr 16, 2026
Dianthus Raises $719M with Upsized Share Offering and Pre-Funded Warrants — Mar 12, 2026
Dianthus Therapeutics’ Price Target Doubles to $200 with 207% Upside — Mar 10, 2026
Dianthus Therapeutics Stock Eyes 79% Upside with $145 Price Target — Mar 9, 2026

DNTH Analyst Consensus

15 analysts cover DNTH: 0 strong buy, 15 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $122.57.

Common questions about DNTH

Who is trading DNTH stock inside the company?: Recent DNTH insider activity includes Soteropoulos Paula sold 599, Savitz Ryan sold 8.22K, Savitz Ryan sold 1.39K, Savitz Ryan sold 21.82K, and Savitz Ryan sold 1.49K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for DNTH?: Yes. Rallies tracks DNTH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is DNTH research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DNTH. It does not provide personalized investment advice.